According to Acumen Research and Consulting, the global transcatheter heart valve replacement market size is expected to reach around US$ 11 billion by 2026 with 12.9 % of CAGR throughout the forecast period 2019-2026.
A heart valve is available in the arteries and veins and allows the blood to flow through the heart in just one direction. The four main valves in the heart are two atrioventricular valves, which is known as the tricuspid valve, and two semi-mountain valves. The atria, ventricles and blood vessels are separated by a cardiac valve. To permit blood flow, a heart valve is pulled open to closing and preventing blood reversal. This closure is tightly sealed by the nodules at the end of the cuspes, which are the heart valve opening leaflets. Valvular heart disease is due to the dysfunction of the heart valve. There are two types of heart disorders: regurgitation or valve failure, where blood is flowing in the wrong direction due to heart dysfunction; and the latter is valve stenosis (severe aortic stenosis). Heart valves that have been injured or defective will be repaired or replaced by artificial heart valves. Valvular heart disease is diagnosed with echocardiography. The aortic valve transcatheter substitute, also known as aortic valve transcatheter implantation, is one of the valve valve valve treatment procedures for replacing the damaged core valve.
The report provides analysis of global Transcatheter Heart Valve Replacement market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
The majority of population over 65 years is cardiovascular disease. Roughly 5% of the world's population above 65 years of age is at risk for heart disease. If the heart valve is not replaced or repaired, 50% of patients with VCD will not survive. Transcatheter cardiovascular valve is used in aortic valve substitution processes for a patient who is unable to undergo an open-heart operation with life-threatening risks. For example, the transcatheter aortic recharge is the viable option for heart patients, heart lung kidney disease or diabetic patients to encounter complications in open heart surgery. In patients suffering from valve aortic valve replacement, higher survival rates have been shown. The period of restoration after insertion of the transcatheter cardiac valve is 7 to 8 days less than other operations. The risk associated with the aortic valve transcatheter replacement process is the limitation of the transcatheter heart valve market. The replacement of the valve and its slippage may be problematic. In the case of transcatheter heart valve replacement procedure, there is a high risk of blood vessel tearing and infection.
In 2018 it was estimated at around USD 3,000 million that the transcatheter aortic valve replacement market had been. A higher prevalence of aortic valve disease will lead to an increasing number of aortic valve transcatheter substitutions. The geriatric population at risk of aortic stenosis is increasing according to recent statistics and is estimated to experience this disease in approximately 2,5 million individuals in the United States over the age of 75. Increased aortic transcatheter valve demand and adoption rates will enhance business growth. It is estimated that over the projection period, the mitral valve market is increasing at a hasty rate of more than 27 %. The increasing prevalence of serious mitral annular calcifications, failing bio-prothesis surgical and unsuccessful operative rings have increased the demand for mitral valves. Recent technological developments and new products development will also lead to substantial growth in the mitral valve transcatheter market in the coming years.
Surgical Approach Stance
Approximately US$ 2.500 million was estimated in the 2018 market for transfemoral approach. Rapid technological advancement to replace transcatheter heart valves has resulted in minimally invasive procedures such as a transfemoral approach to reduce surgery complications and maximize survival. The transfemoral approach is therefore the most preferred method for replacing the coronary valve transcatheter, which will increase the growth of the business in the years to come. A strong CAGR of around 14% is projected to expand over the estimated period on the transaortic approach market. Increased numbers of persons with severe symptom aortic stenosis who can not undergo surgery will in turn increase aortic valve replacement demand and adoption rates, increasing the market for aortic valve replacement approaches.
The use of transcatheter heart valve was estimated to be about USD 3.3 million in 2018, for aortic valve disorders. The increasing geriatric population is leading aortic valvular heart disease because they are more likely to have cardiovascular and other chronic diseases. According to recent research, the next most prevalent heart failure and coronary artery disease is that people over 70 years of age have high blood pressure. The increase in the prevalence of several chronic heart problems will therefore increase the use of transcatheter cardiac valves, fueling business growth over the next few years.
Transcatheter heart valve applications for mitral valve disorders will increase over the forecast timeframe at a lucrative CAGR of around 27 %. The Asia-Pacific and Latin America development regions are estimated to have led to many countries moving to a western style of life with high food-containing fat and an increase in cardio-vascular diseases as a result of the economic development.
End Use Stance
In hospitals, the use of the transcatheter heart valve in 2018 was estimated at about USD 2.500 million. The high market share is due to the availability of state-of - the-art hospital facilities. Valve substitution procedures are usually carried out in the hospital because these operations are complicated and can be trusted in the hospitals by having adequate medical facilities.
In a CAGR of around 14 percent over the expected period, transcatheter cardiac valve usage in the hearth centers can be seen as an impressive growth. Cardiac centers are estimated to hold satisfactory amount of market share in the forthcoming years. It provides the medical facilities needed to treat heart valve transcatheter diseases. Centers for the diagnosis of cardiovascular diseases are designed specifically for the treatment of them.
In 2018, the US dominated the market for heart valve replacement transcatheters in North America and was estimated at some $1.700 million. Valve cardia is one of the most common diseases in the American population. cardiovascular disorder. The growth of the market will enhance an increase in the number of people in the country with valve heart disease. The region's heart valve replacement market will also be enhanced by favorable refund policies and the presence of key market players.
It is estimated that India's heart valve substitution market will increase by 18.0 percent over the predicted period at CAGR. Increasing the geriatric population, increasing numbers of people with valvular heart disease, growing public awareness of heart valve transcatheter therapy and an increase in health care will drive the country's business growth in years to come.
Global Transcatheter Heart Valve Replacement Market, By Product
Global Transcatheter Heart Valve Replacement Market, By Surgical Approach
Global Transcatheter Heart Valve Replacement Market, By Application
Global Transcatheter Heart Valve Replacement Market, By End Use
Global Transcatheter Heart Valve Replacement Market, By Geography
The market research study on “Transcatheter Heart Valve Replacement Systems Market - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Transcatheter Heart Valve
Key Players & Strategies
The Transcatheter Heart Valve Replacement market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players are Edwards Lifesciences, Medtronic Plc, Boston Scientific, Abbott, and others.
Growing progress in existing technology, the introduction of new and new products, geographical expansion and acquisitions and mergers are some of these companies ' strategies for profiting on market opportunities. In December 2018, for example, Meril Life Sciences launched the TVR Myval, the first indian company to produce a heart valve transcatheters and to be sold globally.